Holobiome

Executive Summary

Holobiome is a private, Cambridge-based biotechnology company founded in 2015 with a mission to translate the emerging science of the human microbiome into next-generation probiotics and targeted solutions for whole-body health. The company emphasizes scientific rigor and a passion for improving health, positioning itself at the intersection of biologics and microbiome research. By leveraging the intricate relationship between the gut microbiome and various physiological systems, Holobiome aims to develop novel therapeutic interventions that address a wide range of health conditions, from metabolic disorders to neurological and immune-related diseases. As a privately held entity, Holobiome operates with a focus on research and development, seeking to harness the potential of the microbiome to create products that offer systemic benefits. However, the company remains in the early stages of development, with no disclosed pipeline, funding rounds, or partnerships, making it a high-risk, high-reward opportunity in the competitive microbiome therapeutics space. Its success depends on advancing preclinical candidates into clinical trials and securing strategic collaborations to validate its technology platform. The growing interest in microbiome-based therapies, supported by increasing clinical evidence and regulatory guidance, provides a favorable tailwind for Holobiome's efforts, though the path to commercialization is uncertain without clear milestones or financial backing.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round40% success
• Q1 2027Lead Candidate IND Filing25% success
• Q2 2027Strategic Partnership with Large Pharma30% success